Journal Thoracic Oncology

Recommendations

Info

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017 7 Fujian Cancer Hospital, Fujian/China, 8 Wuhan Union Hospital, Wuhan/China, 9 Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun/China, 10 Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou/China, 11 Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha/ China, 12 Harbin Medical University Cancer Hospital, Harbin/China, 13 Department of Respiratory Medicine, Peking Union Medical College Hosptial, Peking Union Medical College&chinese Academy of Medical Sciences, Beijing, China., Beijing/ China, 14 Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Cancer Center, Beijing/China, 15 Betta Pharmaceuticals Co.,ltd, Beijing/China, 16 Zhongshan Chenxinghai Hospital, Zhongshan/China This abstract is under embargo until December 6, 2016 at 07:00 CET. PL03: PRESIDENTIAL SYMPOSIUM TUESDAY, DECEMBER 6, 2016 - 08:35-10:25 PL03.07 FIRST-LINE CERITINIB VERSUS CHEMOTHERAPY IN PATIENTS WITH ALK-REARRANGED (ALK+) NSCLC: A RANDOMIZED, PHASE 3 STUDY (ASCEND-4) Gilberto De Castro Jr 1 , Daniel Shao-Weng Tan 2 , Lucio Crinò 3 , Yi Long Wu 4 , Luis Paz-Ares 5 , Jürgen Wolf 6 , Sarayut Geater 7 , Sergey Orlov 8 , Diego Cortinovis 9 , Chong-Jen Yu 10 , Maximilian Hochmair 11 , Alexis Cortot 12 , Chun-Ming Tsai 13 , Denis Moro-Sibilot 14 , Rosario García Campelo 15 , Fabrice Branle 16 , Paramita Sen 17 , Tracey Mcculloch 17 , Jean-Charles Soria 18 1 Instituto Do Câncer Do Estado de São Paulo, São Paulo/Brazil, 2 National Cancer Center, Singapore/Singapore, 3 Azienda Ospedale Perugia, Perugia/Italy, 4 Guangdong General Hospital, Guangzhou/China, 5 University Hospital 12 Octubre, Madrid/Spain, 6 University Hospital Cologne, Cologne/Germany, 7 Prince of Songkla University, Songkhla/Thailand, 8 State Pavlov Medical University, St Petersburg/ Russian Federation, 9 Az. Ospedaliera San Gerardo, Monza/Italy, 10 National Taiwan University Hospital, Taipei City/Taiwan, 11 Otto Wagner Hospital, Department of Respiratory and Critical Care Medicine, Vienna/Austria, 12 Lille University Hospital, Lille/France, 13 Taipei Veterans General Hospital, Taipei/Taiwan, 14 CHU de Grenoble, Cedex/France, 15 Complejo Uni. Hosp. A Coruna (Antes Hospital Juan Canalejo), Coruña/France, 16 Novartis Pharma Ag, Basel/Switzerland, 17 Novartis Pharmaceutical Corporation, East Hanover/NJ/United States of America, 18 Institut Gustave Roussy, Villejuif/France This abstract is under embargo until December 6, 2016 at 07:00 CET. PL03: PRESIDENTIAL SYMPOSIUM TUESDAY, DECEMBER 6, 2016 - 08:35-10:25 PL03.09 PHASE 3 STUDY OF GANETESPIB, A HEAT SHOCK PROTEIN 90 INHIBITOR, WITH DOCETAXEL VERSUS DOCETAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER (GALAXY-2) Rathi Pillai 1 , Dean Fennell 2 , Vladimir Kovcin 3 , Tudor Ciuleanu 4 , Rodryg Ramlau 5 , Dariusz Kowalski 6 , Michael Schenker 7 , Branislav Perin 8 , Ilker Yalcin 9 , Florentina Teofilovici 9 , Vojo Vukovic 9 , Suresh Ramalingam 10 1 Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta/GA/United States of America, 2 Cancer Research Uk Centre, University of Leicester & Leicester University Hospitals, Leicester/United Kingdom, 3 Medical Center Bezanijska Kosa, Belgrade/Serbia, 4 Institute of Oncology Ion Chiricuta and Umf Iuliu Hatieganu, Cluj Napoca/Romania, 5 Department of Oncology, Poznan University of Medical Sciences, Poznan/Poland, 6 Department of Lung Cancer and Chest Tumours; the Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw/Poland, 7 Oncolab, Craiova/Romania, 8 Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Sremska Kamenica/Serbia, 9 Synta Pharmaceuticals, Lexington/MA/United States of America, 10 Winship Cancer Institute, Emory University, Atlanta/GA/United States of America This abstract is under embargo until December 6, 2016 at 07:00 CET. 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD/USA; 2 Hospital Universitario Insular de Gran Canaria, Las Palmas/Spain; 3 Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON/Canada; 4 Westmead Hospital and the University of Sydney, Sydney, NSW/ Australia; 5 Jász-Nagykun-Szolnok County Hospital, Szolnok/Hungary; 6 Országos Korányi TBC és Pulmonológiai Intézet, Budapest/Hungary; 7 Meir Medical Center, Kfar-Saba/Israel; 8 Davidoff Cancer Center, Petah Tikva University, Petah Tikva/ Israel; 9 Southern Medical Day Care Centre, Wollongong, NSW/Australia; 10 St. James’s Hospital and Cancer Trials Ireland (formerly ICORG – All Ireland Cooperative Oncology Research Group), Dublin/Ireland; 11 The Royal Marsden Hospital, Sutton, Surrey/UK; 12 MedStar Franklin Square Hospital, Baltimore, MD/USA; 13 Okayama University Hospital, Okayama/Japan; 14 Merck & Co., Inc., Kenilworth, NJ/USA; 15 Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf/Germany This abstract is under embargo until December 7, 2016 at 07:00 CET. SESSION PL04A: IMMUNE CHECKPOINT INHIBITORS IN ADVANCED NSCLC WEDNESDAY, DECEMBER 7, 2016 - 08:45-09:40 PL04A.02 OAK, A RANDOMIZED PH III STUDY OF ATEZOLIZUMAB VS DOCETAXEL IN PATIENTS WITH ADVANCED NSCLC: RESULTS FROM SUBGROUP ANALYSES Shirish Gadgeel 1 , Fortunato Ciardiello 2 , Achim Rittmeyer 3 , Fabrice Barlesi 4 , Diego Cortinovis 5 , Carlos Barrios 6 , Toyoaki Hida 7 , Keunchil Park 8 , Dariusz Kowalski 9 , Manuel Cobo Dols 10 , Joseph Leach 11 , Jonathan Polikoff 12 , Christina Matheny 13 , Pei He 13 , Marcin Kowanetz 13 , Daniel Chen 13 , Daniel Waterkamp 13 , Marcus Ballinger 13 , Alan Sandler 13 , David R. Gandara 14 , Joachim Von Pawel 15 1 Karmanos Cancer Institute/wayne State University, Detroit/MI/United States of America, 2 Seconda Università Degli Studi Di Napoli, Napoli/Italy, 3 Lungenfachklinik Immenhausen, Immenhausen/Germany, 4 Aix-Marseille University; Assistance Publique Hôpitaux de Marseille, Marseille/France, 5 Medical Oncology Unit, Aou San Gerardo, Monza/Italy, 6 Medicine, Pucrs School of Medicine, Porto Alegre/ Brazil, 7 Aichi Cancer Center Hospital, Nagoya/Japan, 8 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/Korea, Republic of, 9 Oncology Centre - Institute M. Sklodowska- Curie, Warsaw/Poland, 10 Medical Oncology Section, Hospital Regional Universitario Carlos Haya, Málaga/Spain, 11 Pra Health Sciences, Raleigh/NC/United States of America, 12 Southern California Permanente Medical Grou, San Diego/CA/United States of America, 13 Genentech, Inc, South San Francisco/CA/United States of America, 14 Division of Hem-Oncology, UC Davis Comprehensive Cancer Center, Sacramento/CA/United States of America, 15 Asklepios-Fachkliniken München-Gauting, Gauting/Germany This abstract is under embargo until December 7, 2016 at 07:00 CET. PL04: IMMUNE CHECKPOINT INHIBITORS IN ADVANCED NSCLC WEDNESDAY, DECEMBER 7, 2016 - 08:45-09:40 PL04A.03 DURVALUMAB IN ≥3RD-LINE LOCALLY ADVANCED OR METASTATIC, EGFR/ALK WILD-TYPE NSCLC: RESULTS FROM THE PHASE 2 ATLANTIC STUDY Marina Garassino 1 , Johan Vansteenkiste 2 , Joo-Hang Kim 3 , Hervé Léna 4 , Julien Mazières 5 , John Powderly 6 , Phillip Dennis 7 , Yifan Huang 7 , Catherine Wadsworth 8 , Naiyer Rizvi 9 1 Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan/Italy, 2 University Hospitals KU Leuven, Leuven/Belgium, 3 CHA Bundang Medical Center, CHA University, Gyeonggi-Do/Korea, Republic of, 4 CHU Rennes - Hôpital Pontchaillou, Rennes/ France, 5 CHU de Toulouse - Hôpital Larrey, Toulouse/France, 6 Carolina Biooncology Institute, Huntersville/NC/United States of America, 7 Astrazeneca, Gaithersburg/ MD/United States of America, 8 Astrazeneca, Alderley Park/United Kingdom, 9 Columbia University Medical Center, New York/NY/United States of America This abstract is under embargo until December 7, 2016 at 07:00 CET. SESSION PL04a: IMMUNE CHECKPOINT INHIBITORS IN ADVANCED NSCLC WEDNESDAY, DECEMBER 7, 2016 - 08:45-09:40 PL04: IMMUNE CHECKPOINT INHIBITORS IN ADVANCED NSCLC WEDNESDAY, DECEMBER 7, 2016 - 08:45-09:40 PL04A.01 HEALTH-RELATED QUALITY OF LIFE FOR PEMBROLIZUMAB VS CHEMOTHERAPY IN ADVANCED NSCLC WITH PD-L1 TPS ≥50%: DATA FROM KEYNOTE-024 Julie R. Brahmer, 1 Delvys Rodríguez-Abreu, 2 Andrew G. Robinson, 3 Rina Hui, 4 Tibor Csőszi, 5 Andrea Fülöp, 6 Maya Gottfried, 7 Nir Peled, 8 Ali Tafreshi, 9 Sinead Cuffe, 10 Mary O’Brien, 11 Suman Rao, 12 Katsuyuki Hotta, 13 Anne C. Deitz, 14 Gregory M. Lubiniecki, 14 Jin Zhang, 14 Reshma Rangwala, 14 Martin Reck 15 PL04A.04 MULTICENTRIC FRENCH HARMONIZATION STUDY FOR PD-L1 IHC TESTING IN NSCLC Julien Adam 1 , Isabelle Rouquette 2 , Diane Damotte 3 , Cécile Badoual 4 , Claire Danel 5 , Francesca Damiola 6 , Frédérique Penault-Llorca 7 , Sylvie Lantuejoul 6 1 Department of Pathology, Gustave Roussy Cancer Campus, Villejuif/France, 2 Department of Pathology, Institut Universitaire Du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse/France, 3 Department of Pathology, Hopital Cochin Aphp, and Centre de Recherche Des Cordeliers, Inserm S4 Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017 Umrs 1138, Paris Descartes 5 University, Paris/France, 4 Department of Pathology, Hopital Européen Georges-Pompidou AP-HP and Inserm U 970, Team 10, Paris Descartes 5 University, Paris/France, 5 Department of Biopathology, Hôpital Bichat- Claude Bernard, AP-HP, and Faculté de Médecine, Université Paris Diderot, Inserm Umr 1152, Paris/France, 6 Biopathology, Cancer Institute Léon Bérard, Lyon/France, 7 Department of Biopathology, Centre Jean Perrin, Clermont-Ferrand, France, Ea 4677 “Ertica”, University of Auvergne, Clermont-Ferrand/France This abstract is under embargo until December 7, 2016 at 07:00 CET. SESSION PL05: CLOSING PLENARY SESSION: A LIFE IN THO- RACIC ONCOLOGY - REFLECTIONS FROM GIANTS ON MILES- TONES IN THE TREATMENT ADVANCES IN LUNG CANCER WEDNESDAY, DECEMBER 7, 2016 - 16:00-18:00 PL05.01 PATHOLOGY Adi Gazdar Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas/TX/United States of America While many regard a pathologist as a physician involved in laboratory diagnosis, by definition Pathology is the science or the study of the origin, nature and course of diseases. This broader definition of pathology, which basically encompasses all of the study of medicine, is what first attracted me to the field. After my residency I joined the NCI as a research pathologist studying viral oncology in rodents. However a few years later John Minna gave me the opportunity to return to the study of human cancer when he was appointed the head of the NCI-VA Medical Oncology Branch in Washington, DC, with a focus on lung cancer therapy. Our branch was fortunate to have an outstanding lung pathologist, Mary Matthews who taught me most of what I know about lung pathology. Mary also had a profound effect on the understanding and treatment of lung cancer. In 1973 she established that small cell lung cancer (SCLC) was almost always metastatic at the time of diagnosis, and that surgery was unlikely to be curative. 1 These observations, plus the finding that SCLC showed initial responses to the therapy then currently available, helped establish the fundamental distinction of lung cancers into SCLC and NSCLC categories. The Mary Matthew award for Pathology and Translational Research is one of the distinguished awards of the IASLC and I was fortunate and honored to be the fourth recipient in 2003. John Minna assembled an outstanding group of physicians/scientist many of whom became pioneers in the field of lung cancer. Of interest, all three past and present Chief Executive Officers of the IASLC, Heine Hansen, Paul Bunn and Fred Hirsch, spent time at the NCI-VA Medical Oncology Branch. John preached that new approaches for the therapy of lung cancer were needed, that this would require understanding biology, and to understand biology we needed preclinical models. My job was to establish such models and help “translate” them into clinical care. By the early 1980s we had established and characterized large banks of SCLC cell lines and demonstrated that they expressed the entire neuroendocrine (NE) cell program. 2 The cell lines were widely distributed to the scientific community, and in the absence of reliable tumor tissue sources, became the major source of biologic and molecular knowledge of SCLC. Within that decade our group, largely from the use of cell lines, described chromosome 3p loss, MYC family amplification, RB1 and TP53 loss as being characteristics of SCLC and also discovered the MYCL oncogene. The NCI-VA Medical Oncology Branch later relocated to the Bethesda Naval Hospital, MD. In 1991, John Minna accepted a position at the University of Texas Southwestern Medical Center, Dallas, and I was his first recruitment. Thus, during my long career I have only had two employers! I believe this continuity has helped establish strong, long term collaborations and boosted overall productivity. One of the interests of Mary Matthews and me was the heterogeneity of SCLC. It became obvious to us that the so-called oat cell variant was an ischemic artifact. However we were intrigued by the plasticity of SCLC, with a substantial percentage of cases having abnormal (“variant”) morphologies or combined with NSCLC elements, especially after therapy. 3 The variant morphology and its relationship to NEUROD1 as the driver transcription factor (as opposed to ASCL1 as the driver in typical or “classic” SCLC) has recently been highlighted. 4 By the mid 1980s, advances in SCLC biology and therapy had hit a stonewall, and funding dried up. It was time to move onto NSCLC! We established a large collection of NSCLC cell lines and these also formed much of the basis of our understanding of this disease, although tumor tissues were much more readily available. While cell lines have their pluses and minuses, they are excellent for identifying driver mutations and testing targeted therapies. They contributed to the identification of the role of EGFR mutations in lung cancer. 5, 6 Soon after this discovery we used our international fellows and contacts to perform the first large multinational study of geographic and ethnic variations in mutation frequencies, and also demonstrated that mutations were largely absent in tumors other than NSCLC. 7 The advent of Precision Medicine has highlighted the crucial role of the pathologist. Instead of the image of a pathologist looking at microscope slides in isolation in a basement office, he or she plays a crucial role as an integral part of the diagnostic and therapeutic team involved in every aspect of patient management. The pathologist assumes further responsibilities such as tissue procurement and optimal utilization, triaging scant resources for clinical trial requirements, involvement in molecular testing, performing requested or required immunostaining, establishing tissue repositories etc. Previously clinical decision making required the pathologist only to make a diagnosis of SCLC or NSCLC. Precision Medicine has highlighted the importance of accurate classification of NSCLC. Classification is required for mutation testing, therapy selection (or exclusion) and entry onto histology dependent clinical trials. While the introduction of immunostains has greatly facilitated the classification of poorly differentiated NSCLC, the SEER database indicates that up to 14% of NSCLC may remain unclassified throughout the USA. For these reasons we developed a molecular classifier for NSCLC that can be applied to formalin fixed paraffin embedded (FFPE) materials and small core biopsies. 8 The assay is highly accurate and quantitative, and also provides information on grading and survival. While SCLC languished for three decades, its recent designation as a recalcitrant cancer by the US Congress has resulted in a dramatic resurrection of interest, funding and achievement. 9 This has highlighted the importance of preclinical models for SCLC. 10, 11 I feel very humbled and privileged to have lived through and contributed to the seminal advances in our understanding of the biology and therapy of lung cancer. This would not have been possible without the many wonderful and talented people I have worked with. I am reminded of the quote of Isaac Newton: “If I have seen further than others, it is because I have stood on the shoulders of giants”.References 1. Matthews MJ, Kanhouwa S, Pickren J, et al. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer chemotherapy reports Part 3 1973;4:63-67. 2. Gazdar AF, Carney DN, Russell EK, et al. Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res 1980;40:3502-3507. 3. Gazdar AF, Carney DN, Nau MM, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res 1985;45:2924-2930. 4. Borromeo MD, Savage TK, Kollipara RK, et al. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell reports 2016;16:1259-1272. 5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500. 6. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181. 7. Shigematsu S, Lin L, Takahashi T, et al. Clinical and biological features associated with Epidermal Growth Factor Receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346. 8. Girard L, Rodriguez-Canales J, Behrens C, et al. An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer. Clin Cancer Res 2016. 9. Gazdar AF, Minna JD. Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer. J Natl Cancer Inst 2016;108. 10. Gazdar AF, Hirsch FR, Minna JD. From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. J Thorac Oncol 2016;11:287-299. 11. Gazdar AF, Savage TK, Johnson JE, et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol 2015;10:553-564. Keywords: Molecular biology, Translational medicine, Pathology, lung cancer PL05: CLOSING PLENARY SESSION: A LIFE IN THORACIC ONCOLOGY - REFLECTIONS FROM GIANTS ON MILESTONES IN THE TREATMENT ADVANCES IN LUNG CANCER WEDNESDAY, DECEMBER 7, 2016 - 16:00-18:00 PL05.02 SURGERY Peter Goldstraw] Academic Department of Thoracic Surgery, National Heart and Lung Institute, Imperial College, Dartmouth/United Kingdom The speaker began his training in Cardiothoracic surgery in 1973 and was appointed as a Consultant in 1979. He will introduce this topic by describing a typical case undergoing surgical treatment for lung cancer in the 1970s, the patient journey and outcomes at that time. From that basis he will detail the changes in the surgical treatment of lung cancer in the last 40 years. This will include: · Changes in the epidemiology of lung cancer. · Improvements in pre-operative selection. · Improvements in the staging process prior to surgery, during surgery and post-surgery. · Differences in surgical approach and the anatomical extent of resection. · Changes in the stage classification over that period. · The establishment of effective adjuvant therapy. · Improved outcomes in morbidity, mortality and survivorship. None of these improvements has been of itself a game changer but collectively they amount Copyright © 2016 by the International Association for the Study of Lung Cancer S5
Page 1 and 2: Volume 12 • Issue S1 • January
Page 3 and 4: Abstracts Journal of Thoracic Oncol
Page 5: Abstracts Journal of Thoracic Oncol
Page 57 and 58:
Abstracts Journal of Thoracic Oncol
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
Page 477 and 478:
Page 479 and 480:
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
Page 491 and 492:
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Page 501 and 502:
Page 503 and 504:
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 533 and 534:
Page 535 and 536:
Page 537 and 538:
Page 539 and 540:
Page 541 and 542:
Page 543 and 544:
Page 545 and 546:
Page 547 and 548:
Page 549 and 550:
Page 551 and 552:
Page 553 and 554:
Page 555 and 556:
Page 557 and 558:
Page 559 and 560:
Page 561 and 562:
Page 563 and 564:
Page 565 and 566:
Page 567 and 568:
Page 569 and 570:
Page 571 and 572:
Page 573 and 574:
Page 575 and 576:
Page 577 and 578:
Page 579 and 580:
Page 581 and 582:
Page 583 and 584:
Page 585 and 586:
Page 587 and 588:
Page 589 and 590:
Page 591 and 592:
Page 593 and 594:
Page 595 and 596:
Page 597 and 598:
Page 599 and 600:
Page 601 and 602:
Page 603 and 604:
Page 605 and 606:
Page 607 and 608:
Page 609 and 610:
Page 611 and 612:
Page 613 and 614:
Page 615 and 616:
Page 617 and 618:
Page 619 and 620:
Page 621 and 622:
Page 623 and 624:
Page 625 and 626:
Page 627 and 628:
Page 629 and 630:
Page 631 and 632:
Page 633 and 634:
Page 635 and 636:
Page 637 and 638:
Page 639 and 640:
Page 641 and 642:
Page 643 and 644:
Page 645 and 646:
Page 647 and 648:
Page 649 and 650:
Page 651 and 652:
Page 653 and 654:
Page 655 and 656:
Page 657 and 658:
Page 659 and 660:
Page 661 and 662:
Page 663 and 664:
Page 665 and 666:
Page 667 and 668:
Page 669 and 670:
Page 671 and 672:
Page 673 and 674:
Page 675 and 676:
Page 677 and 678:
Page 679 and 680:
Page 681 and 682:
Page 683 and 684:
Page 685 and 686:
Page 687 and 688:
Page 689 and 690:
Page 691 and 692:
Page 693 and 694:
Page 695 and 696:
Page 697 and 698:
Page 699 and 700:
Page 701 and 702:
Page 703 and 704:
Page 705 and 706:
Page 707 and 708:
Page 709 and 710:
Page 711 and 712:
Page 713 and 714:
Page 715 and 716:
Page 717 and 718:
Page 719 and 720:
Page 721 and 722:
Page 723 and 724:
Page 725 and 726:
Page 727 and 728:
Page 729 and 730:
Page 731 and 732:
Page 733 and 734:
Page 735 and 736:
Page 737 and 738:
Page 739 and 740:
Page 741 and 742:
Page 743 and 744:
Page 745 and 746:
Page 747 and 748:
Page 749 and 750:
Page 751 and 752:
Page 753 and 754:
Page 755 and 756:
Page 757 and 758:
Page 759 and 760:
Page 761 and 762:
Page 763 and 764:
Page 765 and 766:
Page 767 and 768:
Page 769 and 770:
Page 771 and 772:
Page 773 and 774:
Page 775 and 776:
Page 777 and 778:
Page 779 and 780:
Page 781 and 782:
Page 783 and 784:
Page 785 and 786:
Page 787 and 788:
Page 789 and 790:
Page 791 and 792:
Page 793 and 794:
Page 795 and 796:
Page 797 and 798:
Page 799 and 800:
Page 801 and 802:
Page 803 and 804:
Page 805 and 806:
Page 807 and 808:
Page 809 and 810:
Page 811 and 812:
Page 813 and 814:
Page 815 and 816:
Page 817 and 818:
Page 819 and 820:
Page 821 and 822:
Page 823 and 824:
Page 825 and 826:
Page 827 and 828:
Page 829 and 830:
Page 831 and 832:
Page 833 and 834:
Page 835 and 836:
Page 837 and 838:
Page 839 and 840:
Page 841 and 842:
Page 843 and 844:
Page 845 and 846:
Page 847 and 848:
Page 849 and 850:
Page 851 and 852:
Page 853 and 854:
Page 855 and 856:
Page 857 and 858:
Page 859 and 860:
Page 861 and 862:
Page 863 and 864:
Page 865 and 866:
Page 867 and 868:
Page 869 and 870:
Page 871 and 872:
Page 873 and 874:
Page 875 and 876:
Page 877 and 878:
Page 879 and 880:
Page 881 and 882:
Page 883 and 884:
Page 885 and 886:
Page 887 and 888:
Page 889 and 890:
Page 891 and 892:
Page 893 and 894:
Page 895 and 896:
Page 897 and 898:
Page 899 and 900:
Page 901 and 902:
Page 903 and 904:
Page 905:
Page 912:
LILLY ONCOLOGY IS DEDICATED TO ADVA
show all

Journal Thoracic Oncology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?